Abstract
In the panorama of HIV protease inhibitors (HIV PIs), many efforts have been devoted to the development of new compounds with reduced peptidic nature in order to improve pharmacokinetics and pharmacodynamics features. The introduction of cyclic scaffolds in the design of new chemical entities reduces flexibility and affords more rigid inhibitors. Specifically, common dipeptide isosteres are replaced by a central cyclic scaffold designed to address the key interactions with catalytic aspartic acids and residues belonging to the flap region of the active site. The current interest in cyclic chemotypes addressing key interactions of HIV protease is motivated by the different nature of interactions formed with the enzyme, although maintaining key structural resemblance to a peptide substrate, hopefully giving rise to novel HIV-1 PIs displaying an improved profile towards multidrug resistant strains. This approach has been demonstrated for Tipranavir, which is a potent FDA approved HIV-1 PI representing the most famous example of heterocyclic aspartic protease inhibitors.
Keywords: Amino acid, peptidomimetic, small molecule, enzyme inhibition, infectious disease.
Current Medicinal Chemistry
Title:Heterocyclic HIV-Protease Inhibitors
Volume: 20 Issue: 30
Author(s): C. Calugi, A. Guarna and A. Trabocchi
Affiliation:
Keywords: Amino acid, peptidomimetic, small molecule, enzyme inhibition, infectious disease.
Abstract: In the panorama of HIV protease inhibitors (HIV PIs), many efforts have been devoted to the development of new compounds with reduced peptidic nature in order to improve pharmacokinetics and pharmacodynamics features. The introduction of cyclic scaffolds in the design of new chemical entities reduces flexibility and affords more rigid inhibitors. Specifically, common dipeptide isosteres are replaced by a central cyclic scaffold designed to address the key interactions with catalytic aspartic acids and residues belonging to the flap region of the active site. The current interest in cyclic chemotypes addressing key interactions of HIV protease is motivated by the different nature of interactions formed with the enzyme, although maintaining key structural resemblance to a peptide substrate, hopefully giving rise to novel HIV-1 PIs displaying an improved profile towards multidrug resistant strains. This approach has been demonstrated for Tipranavir, which is a potent FDA approved HIV-1 PI representing the most famous example of heterocyclic aspartic protease inhibitors.
Export Options
About this article
Cite this article as:
Calugi C., Guarna A. and Trabocchi A., Heterocyclic HIV-Protease Inhibitors, Current Medicinal Chemistry 2013; 20 (30) . https://dx.doi.org/10.2174/09298673113209990135
DOI https://dx.doi.org/10.2174/09298673113209990135 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropeptide Systems and Schizophrenia
CNS & Neurological Disorders - Drug Targets Management of Stable COPD: An Update
Current Respiratory Medicine Reviews The Role of Glucose in the Pathogenesis of Alzheimers Disease Revisited:What Does it Tell us About the Therapeutic use of Lithium?
Central Nervous System Agents in Medicinal Chemistry Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Current Pharmaceutical Design The Potential Therapeutic Value of Renin-Angiotensin System Inhibitors in the Treatment of Colorectal Cancer
Current Pharmaceutical Design Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Pharmacological Modulation of Th17
Recent Patents on Inflammation & Allergy Drug Discovery Understanding the Mechanism and Prevention of Arterial Occlusive Thrombus Formation by Anti-Platelet Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets A “Cute” Desensitization of TRPV1
Current Pharmaceutical Biotechnology The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Disorders of Sex Development: A Review
Current Women`s Health Reviews Cellular Entry of HIV: Evaluation of Therapeutic Targets
Current Pharmaceutical Design The Potential of Selected Prostanoid Receptors as Targets in a New Therapeutic Strategy for Allergy and Immune Diseases
Current Drug Safety Insulin Like Growth Factor-I: A Critical Mediator of the Skeletal Response to Parathyroid Hormone
Current Molecular Pharmacology Prospects of Primary Ovarian Insufficiency Patient-Specific Pluripotent Stem Cells for Disease Modeling and Clinical Impacts
Current Women`s Health Reviews Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders – A Focus on the Modulation of Host Tissue Function
Mini-Reviews in Medicinal Chemistry The Effect of Psychological Stress and Social Isolation on Neuroimmunoendocrine Communication
Current Pharmaceutical Design